ZA975773B - Anticonvulsant derivatives useful in treating manic-depressive bipolar disorder - Google Patents

Anticonvulsant derivatives useful in treating manic-depressive bipolar disorder

Info

Publication number
ZA975773B
ZA975773B ZA975773A ZA975773A ZA975773B ZA 975773 B ZA975773 B ZA 975773B ZA 975773 A ZA975773 A ZA 975773A ZA 975773 A ZA975773 A ZA 975773A ZA 975773 B ZA975773 B ZA 975773B
Authority
ZA
South Africa
Prior art keywords
bipolar disorder
derivatives useful
anticonvulsant derivatives
treating manic
depressive bipolar
Prior art date
Application number
ZA975773A
Other languages
English (en)
Inventor
Richard P Shank
Original Assignee
Ortho Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Pharma Corp filed Critical Ortho Pharma Corp
Publication of ZA975773B publication Critical patent/ZA975773B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • HELECTRICITY
    • H04ELECTRIC COMMUNICATION TECHNIQUE
    • H04NPICTORIAL COMMUNICATION, e.g. TELEVISION
    • H04N21/00Selective content distribution, e.g. interactive television or video on demand [VOD]
    • H04N21/40Client devices specifically adapted for the reception of or interaction with content, e.g. set-top-box [STB]; Operations thereof
    • H04N21/43Processing of content or additional data, e.g. demultiplexing additional data from a digital video stream; Elementary client operations, e.g. monitoring of home network or synchronising decoder's clock; Client middleware
    • H04N21/442Monitoring of processes or resources, e.g. detecting the failure of a recording device, monitoring the downstream bandwidth, the number of times a movie has been viewed, the storage space available from the internal hard disk
    • H04N21/44213Monitoring of end-user related data
    • H04N21/44222Analytics of user selections, e.g. selection of programmes or purchase activity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Social Psychology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Signal Processing (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Databases & Information Systems (AREA)
  • Multimedia (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
ZA975773A 1996-06-28 1997-06-27 Anticonvulsant derivatives useful in treating manic-depressive bipolar disorder ZA975773B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2085096P 1996-06-28 1996-06-28
US08/881,008 US5753693A (en) 1996-06-28 1997-06-23 Anticonvulsant derivatives useful in treating manic-depressive bipolar disorder

Publications (1)

Publication Number Publication Date
ZA975773B true ZA975773B (en) 1998-12-28

Family

ID=26693960

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA975773A ZA975773B (en) 1996-06-28 1997-06-27 Anticonvulsant derivatives useful in treating manic-depressive bipolar disorder

Country Status (21)

Country Link
US (1) US5753693A (enExample)
EP (1) EP0932398B1 (enExample)
JP (1) JP2002515875A (enExample)
KR (1) KR20000022233A (enExample)
CN (1) CN1224350A (enExample)
AP (1) AP1401A (enExample)
AT (1) ATE330593T1 (enExample)
AU (1) AU739363B2 (enExample)
BR (1) BR9712783A (enExample)
CA (1) CA2258895C (enExample)
CZ (1) CZ297342B6 (enExample)
DE (1) DE69736183T2 (enExample)
ES (1) ES2267144T3 (enExample)
HU (1) HUP0003381A3 (enExample)
IL (1) IL127714A (enExample)
NO (1) NO317641B1 (enExample)
NZ (1) NZ333565A (enExample)
RU (1) RU2185824C2 (enExample)
SK (1) SK180498A3 (enExample)
WO (1) WO1998000123A1 (enExample)
ZA (1) ZA975773B (enExample)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1143917T3 (da) * 1998-11-17 2004-06-01 Ortho Mcneil Pharm Inc Antikonvulsive derivater egnet til behandling af posttraumatisk stresssygdom
JP2004517029A (ja) * 1998-12-03 2004-06-10 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 精神分裂病の処置のためのトピラメート及び関連誘導体
AU763601B2 (en) 1999-02-08 2003-07-31 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating autism
ES2238999T3 (es) 1999-02-24 2005-09-16 University Of Cincinnati Uso de derivados de sulfamato para tratar trastornos en el control de los impulsos.
MXPA01010217A (es) 1999-04-08 2005-09-08 Johnson & Johnson Derivados anticonvulsivos utiles en el tratamiento de trastornos neurodegenerativos cronicos.
US6420369B1 (en) 1999-05-24 2002-07-16 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating dementia
US7056890B2 (en) 1999-06-14 2006-06-06 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
WO2000076493A1 (en) 1999-06-14 2000-12-21 Thomas Najarian Combination therapy for effecting weight loss and treating obesity
US20080103179A1 (en) * 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
US7659256B2 (en) * 1999-06-14 2010-02-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US7553818B2 (en) * 1999-06-14 2009-06-30 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US20080255093A1 (en) * 1999-06-14 2008-10-16 Tam Peter Y Compositions and methods for treating obesity and related disorders
US7674776B2 (en) * 1999-06-14 2010-03-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US6191117B1 (en) * 2000-07-10 2001-02-20 Walter E. Kozachuk Methods of producing weight loss and treatment of obesity
AU2001280865A1 (en) 2000-08-02 2002-02-13 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful for the treatment of depression
WO2002043731A2 (en) 2000-11-30 2002-06-06 University Of Florida Treatments for neurogenetic disorders, impulse control disorders, and wound healing
US7041650B2 (en) * 2001-07-09 2006-05-09 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivative salts
WO2003020289A1 (en) * 2001-08-30 2003-03-13 Ortho-Mcneil Pharmaceutical, Inc. Treatment of dementia and memory disorders with anticonvulsants and acetylcholinesterase inhibitors
US20040235957A1 (en) * 2001-10-12 2004-11-25 David Bleakman Use of sulfonamide derivatives as pharmaceuticals compounds
US20050025791A1 (en) * 2002-06-21 2005-02-03 Julius Remenar Pharmaceutical compositions with improved dissolution
US20100311701A1 (en) * 2002-02-15 2010-12-09 Transform Pharmaceuticals, Inc Pharmaceutical Co-Crystal Compositions
US6559293B1 (en) * 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
US20090088443A1 (en) * 2002-02-15 2009-04-02 Julius Remenar Novel crystalline forms of conazoles and methods of making and using the same
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US7790905B2 (en) * 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
WO2003074474A2 (en) * 2002-03-01 2003-09-12 University Of South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient
US20070059356A1 (en) * 2002-05-31 2007-03-15 Almarsson Oern Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
NZ537543A (en) * 2002-07-29 2007-08-31 Alza Corp Formulations and high dose osmotic dosage forms for controlled delivery of topiramate
US7196209B2 (en) * 2002-10-31 2007-03-27 Ortho-Mcneil Pharmaceutical, Inc. Continuous process for the preparation of fructopyranose sulfamate derivatives
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
US20050070524A1 (en) * 2003-06-06 2005-03-31 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and an anticonvulsant agent for the treatment of central nervous system disorders
MXPA06007510A (es) * 2003-12-29 2009-06-10 Johnson & Johnson Composiciones de farmaco y formas de dosis novedosas de topiramato.
MY147767A (en) * 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
TW200612905A (en) * 2004-06-16 2006-05-01 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
PE20060500A1 (es) * 2004-08-24 2006-07-13 Janssen Pharmaceutica Nv Derivados de heteroaril sulfamida benzo-fusionada como anticonvulsivantes
BRPI0610864A2 (pt) * 2005-05-20 2010-08-03 Janssen Pharmaceutica Nv processo para preparação de derivados de sulfamida
US20070155827A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
US20070155823A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
US8716231B2 (en) * 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
AR058389A1 (es) * 2005-12-19 2008-01-30 Janssen Pharmaceutica Nv Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad
US8497298B2 (en) * 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8691867B2 (en) * 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8937096B2 (en) * 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US20070191450A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Mania and Bipolar Disorder
US20070191474A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
US20070191449A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Depression
JP2009537635A (ja) * 2006-05-19 2009-10-29 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 癲癇の処置のための共同−療法
US9744137B2 (en) * 2006-08-31 2017-08-29 Supernus Pharmaceuticals, Inc. Topiramate compositions and methods of enhancing its bioavailability
EP2394643B1 (en) 2006-11-17 2015-09-02 Supernus Pharmaceuticals, Inc. Sustained-release formulations of topiramate
CN102114002B (zh) 2006-12-04 2016-05-11 苏佩努斯制药公司 托吡酯的增强的立即释放制剂
US20090247616A1 (en) * 2008-03-26 2009-10-01 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety
US20090247617A1 (en) * 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
US8580298B2 (en) 2008-06-09 2013-11-12 Vivus, Inc. Low dose topiramate/phentermine composition and methods of use thereof
US20090304789A1 (en) 2008-06-09 2009-12-10 Thomas Najarian Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders
PE20110060A1 (es) 2008-06-23 2011-01-31 Janssen Pharmaceutica Nv Forma cristalina de (2s)-(-)-n-(6-cloro-2,3-dihidro-benzo[1,4]dioxin-2-ilmetil)-sulfamida
US8815939B2 (en) * 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
WO2020104837A1 (en) 2018-11-21 2020-05-28 Rosemont Pharmaceuticals Limited Oral topiramate suspension formulations with extended shelf stability and enhanced bioavailability

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
RU2050852C1 (ru) * 1992-06-05 1995-12-27 Замощина Татьяна Алексеевна Способ пролонгирования биологической активности солей лития
US5384327A (en) * 1992-12-22 1995-01-24 Mcneilab, Inc. Anticonvulsant sorbopyranose sulfamates

Also Published As

Publication number Publication date
SK180498A3 (en) 2000-03-13
IL127714A (en) 2004-08-31
CA2258895C (en) 2006-06-06
BR9712783A (pt) 2000-10-24
WO1998000123A1 (en) 1998-01-08
CZ427798A3 (cs) 1999-08-11
NZ333565A (en) 2000-07-28
ATE330593T1 (de) 2006-07-15
EP0932398B1 (en) 2006-06-21
NO317641B1 (no) 2004-11-29
KR20000022233A (ko) 2000-04-25
IL127714A0 (en) 1999-10-28
NO986051D0 (no) 1998-12-22
NO986051L (no) 1999-02-23
AP9801427A0 (en) 1998-12-31
RU2185824C2 (ru) 2002-07-27
HUP0003381A2 (hu) 2001-05-28
HUP0003381A3 (en) 2001-12-28
ES2267144T3 (es) 2007-03-01
DE69736183D1 (de) 2006-08-03
AU3409697A (en) 1998-01-21
EP0932398A1 (en) 1999-08-04
JP2002515875A (ja) 2002-05-28
CN1224350A (zh) 1999-07-28
CA2258895A1 (en) 1998-01-08
CZ297342B6 (cs) 2006-11-15
AP1401A (en) 2005-04-29
US5753693A (en) 1998-05-19
AU739363B2 (en) 2001-10-11
DE69736183T2 (de) 2007-04-26

Similar Documents

Publication Publication Date Title
AP9801427A0 (en) Anticonvulsant derivatives useful in treating manic depressive bipolar disorder
ZA975772B (en) Anticonvulsant derivatives useful in treating obesity
AP9801428A0 (en) Anticonvulsant derivatives useful in treating amyothrophic lateral sclerosis (als)
GB2285523B (en) Improvements in or relating to multilevel convertors
GB9609641D0 (en) Compounds useful in therapy
GB9605175D0 (en) Improvements in or relating to securing apparatus
EP1015869A4 (en) MICRO IMAGING SYSTEM
ZA975769B (en) Anticonvulsant derivatives useful in treating acute ischemia-induced neurodegeneration
IL129276A (en) Anticonvulsant derivatives useful in treating neuropathic pain
DE69732623D1 (en) Analogsignalmultiplexer in strombetriebsart
HUP0105037A3 (en) Anticonvulsant derivatives useful in treating post traumatic stress disorder
ZA975770B (en) Anticonvulsant derivatives useful in treating psoriasis
GB9604400D0 (en) Compounds useful in therapy
GB9623387D0 (en) Improvements in or relating to feed assemblies
GB9404684D0 (en) Improvements in locking means
GB2315212B (en) Improvements in or relating to shower apparatus
SI0964681T1 (en) Anticonvulsant derivatives useful in treating psoriasis
GB2319543B (en) Improvements in cladding
GB9607405D0 (en) Improvements in or relating to rendering
AUPN237995A0 (en) Improvements in rail carriages
GB9618580D0 (en) Improvements in bio-reactors
GB9521694D0 (en) Improvements in electrophoresis
GB9502842D0 (en) Improvements in trolleys
CA78696S (en) Traction bar
GB9609810D0 (en) Improvements in electrochemistry